The company has published evidence that its TF estimation technique could potentially guide clinical follow-up decisions in cases with a negative liquid biopsy result.
Fulgent Genetics Preliminary Q1 Revenues Exceed Guidance; Firm to Acquire Inform Diagnostics
Fulgent plans to leverage the Texas-based pathology lab's established commercial organization and managed care relationships.
Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug
The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C.
FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.
Roche Reports Flat Diagnostics Revenues in H1
At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business.